Pharmaceutical intelligence for DalCor Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Assets: 1

Recent signals(1)

ClinicalJune 23, 2026

Phase 3 Trial of Dalcetrapib in ACS Patients with AA Genotype Initiated by DalCor Pharmaceuticals

DalCor Pharmaceuticals is initiating a phase 3 trial evaluating the effect of Dalcetrapib on cardiovascular risk in patients with recent acute coronary syndrome (ACS) and a specific genetic profile.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJune 23, 2026

Phase 3 Trial of Dalcetrapib in ACS Patients with AA Genotype Initiated by DalCor Pharmaceuticals

DalCor Pharmaceuticals is initiating a phase 3 trial evaluating the effect of Dalcetrapib on cardiovascular risk in patients with recent acute coronary syndrome (ACS) and a specific genetic profile.

Competitive activity

No signals indexed for this entity yet.

Assets

Dalcetrapib →

Therapeutic areas

ACS →

Cardiovascular →

Cardiovascular · ACS →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.